Tukysa® Tablets for HER2-Positive Breast Cancer

Tukysa® is a prescription tablet used with other medicines to treat certain HER2-positive cancers. This page explains how the treatment works, safe use basics, and your ordering steps with US delivery from Canada. It also outlines ways to manage Tukysa without insurance.

What Tukysa Is and How It Works

Border Free Health connects U.S. patients with licensed Canadian partner pharmacies; prescriptions are verified with prescribers before dispensing.

This medicine contains tucatinib, a small-molecule tyrosine kinase inhibitor that selectively targets the HER2 receptor. By blocking downstream HER2 signaling, the tablets help slow cancer cell growth and survival. It is taken with other approved therapies. For metastatic breast cancer, this treatment is used with trastuzumab and capecitabine. For certain metastatic colorectal cancers, it is used with trastuzumab after prior anti-HER2 therapy, when appropriate.

Results depend on your diagnosis, prior treatments, and overall health. Your oncology team will confirm whether adding this therapy fits your plan and will monitor labs and tolerance during use.

Who It’s For

The tablets are indicated for adults with unresectable or metastatic HER2-positive breast cancer who have received prior anti-HER2 therapy. They are taken with trastuzumab and capecitabine. They are also indicated, in combination with trastuzumab, for RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer after prior anti-HER2 therapy. Patients with known liver problems, severe uncontrolled diarrhea, or who are pregnant should discuss risks carefully. People who can become pregnant should use effective contraception during treatment and for a period after the last dose as directed on the label.

Dosage and Usage

The usual labeled dose is 300 mg by mouth twice daily. Take doses about 12 hours apart consistently. Swallow tablets whole with water. Do not crush, split, or chew. This therapy is used with other agents: trastuzumab and capecitabine for certain breast cancers, or trastuzumab for some colorectal cancers. Your prescriber will set schedules for each medicine and for bloodwork and monitoring. If side effects occur, the care team may adjust treatment per the official label.

Take with or without food. Try to take doses at the same times each day to support adherence. If vomiting occurs after a dose, do not take an extra dose; resume at the next scheduled time. Consult the prescribing information or your oncology team for label-based guidance when unsure.

Strengths and Forms

This therapy is available as film-coated oral tablets. Two strengths are commonly available to support titration and combination therapy. Many patients use a mix of tablets to reach the prescribed total daily dose. Availability may vary by partner pharmacy and by market.

Common presentations include tucatinib 150 mg tablets and 50 mg tablets. Your prescription label will specify which bottles to use and how many tablets to take with each dose.

Missed Dose and Timing

If you miss a dose, skip it and take the next dose at the regular time. Do not double up to make up a missed dose. Keep a simple reminder, such as a phone alert or pill organizer, to support steady dosing. If you are unsure what to do after multiple missed doses, review the official labeling and contact your care team.

Storage and Travel Basics

Store tablets at room temperature in the original, child-resistant container. Keep the bottle tightly closed and protect it from moisture. Do not store in the bathroom. Keep out of reach of children and pets. When traveling, carry medicine in your hand luggage in the original labeled bottle, along with a copy of your prescription. Allow extra time for security screening, and avoid leaving the bottle in a hot vehicle. If your trip spans time zones, keep roughly 12 hours between doses and ask your prescriber how to adjust if needed. For online orders, encrypted checkout helps protect your information.

Benefits

This treatment offers a targeted approach for HER2-positive disease. It may be used after prior HER2-directed therapies. Oral dosing can fit into daily routines, and it is combined with other approved agents for a coordinated regimen. Your team will monitor how you respond and whether adjustments are needed to maintain tolerability.

Side Effects and Safety

• Diarrhea, which can be severe if not managed early
• Nausea or vomiting
• Fatigue or weakness
• Hand-foot syndrome when used with capecitabine
• Abdominal pain or decreased appetite
• Rash, dry skin, or mouth sores
• Headache
• Abnormal liver tests

Serious risks can include severe diarrhea with dehydration, significant liver injury, and embryo-fetal toxicity. Routine blood tests are recommended to monitor liver function. Tell your clinician right away about yellowing of the skin or eyes, dark urine, severe abdominal pain, or persistent diarrhea. Read the Medication Guide and full Prescribing Information before starting.

Drug Interactions and Cautions

Some medicines can raise or lower tucatinib levels. Strong CYP2C8 inhibitors may increase exposure. Strong CYP2C8 or CYP3A inducers may reduce exposure and effectiveness. The treatment may affect certain transporters and could change exposure to sensitive substrates; your clinician will review your full medication list. Tell your team about all prescription and over-the-counter medicines, vitamins, and herbal supplements. Limit alcohol if advised. Use reliable contraception as directed, and do not breastfeed during treatment and for a period after the last dose per the label.

What to Expect Over Time

Therapy is typically continued until disease progression or unacceptable toxicity. Many patients require routine blood tests and periodic scans. Side effects often occur early and can be managed with supportive care and adjustments per the label. Keeping a simple symptom diary and bringing it to appointments can help your care team refine your plan. Consistent daily dosing supports steady exposure and may improve treatment continuity.

Compare With Alternatives

Other targeted options may be used in different breast cancer subtypes or prior lines of care. For hormone receptor–positive disease, CDK4/6 inhibitors are common. Your oncologist selects agents based on tumor markers and prior therapy. Two oral options we carry include Truqap® Capivasertib and Kisqali®. These are not HER2-targeted and are used in different clinical settings; discuss suitability with your prescriber.

Pricing and Access

You can review Canadian pricing and current availability, then place your order for fulfilment that Ships from Canada to US. For questions about coverage, our team can outline typical cash-pay approaches and documents your insurer may request.

Many shoppers search for Tukysa price to understand budget impact across refill cycles. If you are exploring manufacturer or third-party offers, we list any current site promotions on our Promotions page without guarantees. Some patients also look for Tukysa coupon details; availability and eligibility vary by program and prescriber requirements.

If you’re comparing options, see our condition pages for context: Her2 Positive Breast Cancer and Breast Cancer. You can also browse the broader Cancer category and check items sourced from Canada.

Availability and Substitutions

Supply can vary by strength and bottle size. If a particular configuration is unavailable, your prescriber may recommend a therapeutically appropriate alternative or a different strength combination. Requests to Buy tucatinib are processed only with a valid prescription and pharmacist review. We coordinate with your clinician when verification is required.

Patient Suitability and Cost-Saving Tips

This therapy may not suit people with significant liver impairment, persistent uncontrolled diarrhea, or during pregnancy. Your clinician will assess risks and benefits alongside prior HER2-directed treatments. For savings, consider multi-month fills when clinically appropriate to cut repeat fees, and set refill reminders so you don’t miss doses. Using one pharmacy for your combination regimen can streamline coordination. Keep a simple medication list to avoid interaction-related delays. If you’re new to targeted therapy, these articles may help: Afinitor Uses, Fulvestrant Injection, Exemestane Guide, Breast Cancer Awareness, and Ibrance Palbociclib.

Questions to Ask Your Clinician

• Is my cancer confirmed as HER2-positive, and how does that guide therapy?
• How will this tablet be scheduled with trastuzumab and capecitabine?
• Which side effects should prompt a same-day call to your office?
• What lab monitoring will I need, and how often?
• Which medicines, vitamins, or herbal products should I avoid?
• If I have diarrhea, what are the first steps I should take?
• Could a multi-month fill be appropriate to reduce refill frequency?

Authoritative Sources

FDA Prescribing Information

DailyMed Drug Label

Health Canada DPD

Ready to proceed? Add Tukysa tablets to your cart for prompt, express shipping with US shipping from Canada. Always use as prescribed and review the official label for complete directions.